This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Future of DrugDelivery and Combination Product Device Design. The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products.
In the dynamic landscape of the healthcare sector, the evolution of drugdelivery systems plays a significant role in transforming the management of chronic diseases. They are generally used in combination with primary containers, such as prefilled syringes and cartridges.
3a will continue to advance its industrial design, product usability, labelling compliance, regulatory approval, and production planning work in parallel to its validation studies. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.
With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drugdelivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. Ahmad Doroudian, CEO of BetterLife.
is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drugdelivery platform technologies. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. About BetterLife Pharma Inc. BetterLife Pharma Inc.
Public health and regulatory compliance entities depend on bureaucratic leadership to run effectively. Big pharmaceutical companies require a system of hierarchy to accurately adhere to the legal and regulatory requirements for drugdelivery, drug approval, supply chain and manufacturing processes.
They offer several advantages over traditional drugdelivery systems ( such as vials and syringes ), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination. Prefilled syringes are syringes that come pre-filled with a specific dose of medication.
Utilizing drugdelivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV).
Utilizing drugdelivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.
is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drugdelivery platform technologies. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. About BetterLife Pharma Inc. BetterLife Pharma Inc.
There are newer agents coming to the market, for instance, Fc receptor via monoclonal IgG antibodies mechanism, BTK [Bruton tyrosine kinase] inhibition, and so on, however, the real challenge lies in the compliance in terms of patients perspectives such as cost and tolerance.
His broad leadership experience in the pharmaceutical industry, from intellectual property and regulatory compliance to product manufacturing and distribution, presents an exciting opportunity for XPhyto,” said Hugh Rogers, CEO of XPhyto. Thoresen is an important addition to XPhyto’s board of directors. XPhyto Therapeutics Corp.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content